The 5 most recent market catalysts affecting $ATOS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 10, 2026
Corporate Catalyst
Neutral
Impact 65
Atossa Therapeutics Reports Third Quarter 2026 Financial Results
Atossa Therapeutics, a clinical-stage biopharmaceutical company, released its third-quarter 2026 financial results. This filing is important as it provides transparency into the co…
Oct 9, 2026
Corporate Catalyst
Neutral
Impact 65
Atossa Therapeutics Inks Stapled Contingent Value Rights Agreement With VStock Transfer; Atossa Declares Dividend Of One Stapled CVR For Each Share Of Atossa Common Stock
Atossa Therapeutics has formalized its previously announced plan to issue Stapled Contingent Value Rights (CVRs) by entering into an agreement with VStock Transfer and declaring a …
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 55
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
Ascendiant Capital's analyst Edward Woo maintained a 'Buy' rating on Atossa Therapeutics and slightly increased the price target from $24 to $25. This action signals continued posi…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 92
Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
Atossa Therapeutics (ATOS) announced Q2 EPS of $(0.95), which technically 'beat' the analyst consensus estimate of $(1.02). While beating estimates can sometimes be seen positively…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 55
Atossa Therapeutics Presents Mechanism-Driven (Z)-Endoxifen Data In McCune-Albright Syndrome At 2026 AACR Special Conference In Cancer Research
Atossa Therapeutics announced that it presented preclinical data for its drug (Z)-Endoxifen at a specialized cancer research conference. The data suggests that (Z)-Endoxifen, which…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.